156 related articles for article (PubMed ID: 15025915)
1. P-chirality-dependent immune activation by phosphorothioate CpG oligodeoxynucleotides.
Krieg AM; Guga P; Stec W
Oligonucleotides; 2003; 13(6):491-9. PubMed ID: 15025915
[TBL] [Abstract][Full Text] [Related]
2. A dinucleotide motif in oligonucleotides shows potent immunomodulatory activity and overrides species-specific recognition observed with CpG motif.
Kandimalla ER; Bhagat L; Zhu FG; Yu D; Cong YP; Wang D; Tang JX; Tang JY; Knetter CF; Lien E; Agrawal S
Proc Natl Acad Sci U S A; 2003 Nov; 100(24):14303-8. PubMed ID: 14610275
[TBL] [Abstract][Full Text] [Related]
3. Stereo-enriched phosphorothioate oligodeoxynucleotides: synthesis, biophysical and biological properties.
Yu D; Kandimalla ER; Roskey A; Zhao Q; Chen L; Chen J; Agrawal S
Bioorg Med Chem; 2000 Jan; 8(1):275-84. PubMed ID: 10968287
[TBL] [Abstract][Full Text] [Related]
4. Accessible 5'-end of CpG-containing phosphorothioate oligodeoxynucleotides is essential for immunostimulatory activity.
Yu D; Zhao Q; Kandimalla ER; Agrawal S
Bioorg Med Chem Lett; 2000 Dec; 10(23):2585-8. PubMed ID: 11128629
[TBL] [Abstract][Full Text] [Related]
5. Impact of modifications of heterocyclic bases in CpG dinucleotides on their immune-modulatory activity.
Vollmer J; Weeratna RD; Jurk M; Davis HL; Schetter C; Wüllner M; Wader T; Liu M; Kritzler A; Krieg AM
J Leukoc Biol; 2004 Sep; 76(3):585-93. PubMed ID: 15218053
[TBL] [Abstract][Full Text] [Related]
6. Phosphorothioate oligodeoxyribonucleotides induce in vitro proliferation of chicken B-cells.
Wattrang E
Vet Immunol Immunopathol; 2009 Oct; 131(3-4):218-28. PubMed ID: 19447503
[TBL] [Abstract][Full Text] [Related]
7. Stability of stereoregular oligo(nucleoside phosphorothioate)s in human plasma: diastereoselectivity of plasma 3'-exonuclease.
Koziołkiewicz M; Wójcik M; Kobylańska A; Karwowski B; Rebowska B; Guga P; Stec WJ
Antisense Nucleic Acid Drug Dev; 1997 Feb; 7(1):43-8. PubMed ID: 9055038
[TBL] [Abstract][Full Text] [Related]
8. Phosphorothioate backbone modification modulates macrophage activation by CpG DNA.
Sester DP; Naik S; Beasley SJ; Hume DA; Stacey KJ
J Immunol; 2000 Oct; 165(8):4165-73. PubMed ID: 11035048
[TBL] [Abstract][Full Text] [Related]
9. A novel function of phosphorothioate oligodeoxynucleotides as chemoattractants for primary macrophages.
Baek KH; Ha SJ; Sung YC
J Immunol; 2001 Sep; 167(5):2847-54. PubMed ID: 11509631
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms and applications of immune stimulatory CpG oligodeoxynucleotides.
Krieg AM
Biochim Biophys Acta; 1999 Dec; 1489(1):107-16. PubMed ID: 10807001
[TBL] [Abstract][Full Text] [Related]
11. Effect of chemical modifications of cytosine and guanine in a CpG-motif of oligonucleotides: structure-immunostimulatory activity relationships.
Kandimalla ER; Yu D; Zhao Q; Agrawal S
Bioorg Med Chem; 2001 Mar; 9(3):807-13. PubMed ID: 11310616
[TBL] [Abstract][Full Text] [Related]
12. Combined CpG and poly I:C stimulation of monocytes results in unique signaling activation not observed with the individual ligands.
Arsenault RJ; Kogut MH; He H
Cell Signal; 2013 Nov; 25(11):2246-54. PubMed ID: 23876795
[TBL] [Abstract][Full Text] [Related]
13. Induction of interleukin-6 and interleukin-12 in bovine B lymphocytes, monocytes, and macrophages by a CpG oligodeoxynucleotide (ODN 2059) containing the GTCGTT motif.
Zhang Y; Shoda LK; Brayton KA; Estes DM; Palmer GH; Brown WC
J Interferon Cytokine Res; 2001 Oct; 21(10):871-81. PubMed ID: 11711000
[TBL] [Abstract][Full Text] [Related]
14. Novel oligodeoxynucleotide agonists of TLR9 containing N3-Me-dC or N1-Me-dG modifications.
Putta MR; Zhu F; Li Y; Bhagat L; Cong Y; Kandimalla ER; Agrawal S
Nucleic Acids Res; 2006; 34(11):3231-8. PubMed ID: 16798912
[TBL] [Abstract][Full Text] [Related]
15. Oligodeoxynucleotides lacking CpG dinucleotides mediate Toll-like receptor 9 dependent T helper type 2 biased immune stimulation.
Vollmer J; Weeratna RD; Jurk M; Samulowitz U; McCluskie MJ; Payette P; Davis HL; Schetter C; Krieg AM
Immunology; 2004 Oct; 113(2):212-23. PubMed ID: 15379982
[TBL] [Abstract][Full Text] [Related]
16. The immunostimulatory activity of phosphorothioate CpG oligonucleotides is affected by distal sequence changes.
Roberts TL; Dunn JA; Sweet MJ; Hume DA; Stacey KJ
Mol Immunol; 2011 Apr; 48(8):1027-34. PubMed ID: 21324527
[TBL] [Abstract][Full Text] [Related]
17. G3139 and other CpG-containing immunostimulatory phosphorothioate oligodeoxynucleotides are potent suppressors of the growth of human tumor xenografts in nude mice.
Gekeler V; Gimmnich P; Hofmann HP; Grebe C; Römmele M; Leja A; Baudler M; Benimetskaya L; Gonser B; Pieles U; Maier T; Wagner T; Sanders K; Beck JF; Hanauer G; Stein CA
Oligonucleotides; 2006; 16(1):83-93. PubMed ID: 16584297
[TBL] [Abstract][Full Text] [Related]
18. Immunostimulatory activity of CpG containing phosphorothioate oligodeoxynucleotide is modulated by modification of a single deoxynucleoside.
Zhao Q; Yu D; Agrawal S
Bioorg Med Chem Lett; 2000 May; 10(10):1051-4. PubMed ID: 10843214
[TBL] [Abstract][Full Text] [Related]
19. Immunostimulatory activity of CpG oligonucleotides containing non-ionic methylphosphonate linkages.
Yu D; Kandimalla ER; Zhao Q; Cong Y; Agrawal S
Bioorg Med Chem; 2001 Nov; 9(11):2803-8. PubMed ID: 11597460
[TBL] [Abstract][Full Text] [Related]
20. Synthesis of phosphorothioate oligonucleotides with stereodefined phosphorothioate linkages.
Guga P; Stec WJ
Curr Protoc Nucleic Acid Chem; 2003 Oct; Chapter 4():Unit 4.17. PubMed ID: 18428907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
